Physician profile
Kimberly H Laborde
NPI 1902117781
$14,034.46
in general payments reported to CMS, 2019-2025
41 companies · $5,421 in 2025
The $5,421 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,201 · 2022: $1,781 · 2023: $2,275 · 2024: $3,357 · 2025: $5,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,198 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Education: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,198.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Education | $355.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,522.93 | 2021-2025 | |
| Janssen Biotech, INC. | $1,905.07 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $945.59 | 2021-2025 | |
| Lilly USA, LLC | $501.73 | 2021-2025 | Taltz, Ebglyss, Jardiance |
| Pfizer INC. | $474.84 | 2021-2025 | |
| Ucb, INC. | $293.58 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $287.17 | 2021-2025 | Adbry, Anzupgo |
| Corium, LLC | $245.81 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $197.17 | 2021-2025 | |
| Novo Nordisk INC | $173.13 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $156.04 | 2021-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $144.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.89 | 2023-2025 | Trintellix |
| Incyte Corporation | $121.07 | 2021-2024 | Opzelura |
| Axsome Therapeutics, INC. | $111.07 | 2023-2025 | Auvelity |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Laborde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.